60531-34-2

Upstream product

• 60783-90-6 5-bromo-2-ethoxy-benzoic acid 
• 62871-12-9 5-chloro-2-ethoxybenzoic acid 

Downstream Products

• 64506-99-6 β-[4-(2-ethoxy-5-chlorobenzamido)-phenyl]-propionic acid 
• 60531-19-3 4-(2-<2-ethoxy-5-chloro-benzamido>-ethyl)-benzoic acid 
• 62910-23-0 {4-[2-(5-Chloro-2-ethoxy-benzoylamino)-ethyl]-phenyl}-acetic acid 
• 60531-31-9 4-(2-<2-ethoxy-5-chloro-benzamido>-ethyl)-benzoic acid ethyl ester 
• 83639-32-1 4-(2-ethoxy-5-chloro-benzamido)-3-methyl-benzoic acid 
• 83639-33-2 4-(2-ethoxy-5-chloro-benzamido)-2-methyl-benzoic acid 
• 83639-34-3 4-(2-ethoxy-5-chloro-benzamido)-2-methoxy-benzoic acid 
• 60531-07-9 4-(2-<2-ethoxy-5-chloro-benzamido>-propyl)-benzoic acid 
• 62910-11-6 4-(2-ethoxy-5-chlorobenzamido)-phenyl-acetic acid 
• 60531-29-5 4-(2-<2-ethoxy-5-chloro-benzamido>-ethyl)-benzoic acid methyl ester 
• 60531-30-8 4-(2-<5-chloro-2-phenoxy-benzamido>-ethyl)-benzoic acid methyl ester 
• 62910-18-3 4-(2-ethoxy-5-chlorobenzamidomethyl)-phenylacetic acid 
• 81268-51-1 N-(1H-Benzoimidazol-2-yl)-5-chloro-2-ethoxy-benzamide 
• 62910-41-2 ethyl 4-(2-ethoxy-5-chlorobenzamido)-phenylacetate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.